Compound Screening TRIZ Cases

Engineered yeast and mammalian cell models express amyloid beta to screen for compounds that mitigate toxicity in neurodegenerative disease research.

Microcapillary arrays isolate viable protein samples after optical detection, resolving the trade-off between throughput and sample integrity.

Genetically engineered recombinant molecules target drug-resistant bacteria through ion channel formation, shortening the antibiotic development cycle.

Modulating annexin core domain interactions with C-type lectin receptors and LRP-1 to identify therapeutic compounds.

A ligand-guided selection method displaces aptamers using a specific antibody to isolate high-affinity binders.

Replacing costly mammalian models, this method uses C. elegans to assess synergistic effects of tenuazonic acid and patulin on growth and reproduction.

A formulation using bisabolol and glycerol ether ratios mitigates irritation from niacinamide and N-undecylenoyl-L-phenylalanine combinations.

Engineered chimeric Gαs subunits enable high-throughput ligand screening across diverse G protein-coupled receptors.

Genetically encoded calcium indicators replace invasive synthetic dyes to enable precise, repeated in vivo measurements of neural activity.

Formula compounds detect hydrogen peroxide through bioluminescence, bypassing horseradish peroxidase instability at high pH.

A protease biosensor uses specific cleavage sites to detect SARS-CoV-2 activity.

A transgenic mouse model with Prss56-driven Nf1 inactivation develops cutaneous and plexiform neurofibromas.

Antagonists suppress bitter taste receptor activity to improve food palatability and pharmaceutical compliance.

RNA interference sequences targeting C43 mRNA inhibit cell migration, while demethylation inhibitors increase promoter methylation to reduce metastasis.

Stable cell lines expressing functional voltage-gated sodium channels enable reliable membrane potential assays.

Extracted Fc domains eliminate IgA allergens and lot-to-lot impurities from traditional IVIG while preserving therapeutic efficacy.

BLT2 inhibitors suppress leukotriene B4 receptor signaling to reduce airway inflammation.

Monitoring CD3+CD4+CD57+ILT2+ T cells enables early detection of chronic lung allograft dysfunction before irreversible fibro-proliferative lesions develop.

A binary complex links a test compound to a presenter protein to modulate target biological activity.

Chaperones inhibit Z-AT polymerization in the endoplasmic reticulum, resolving liver toxicity while restoring lung function.

Identifying the HGFR IPT-3/IPT-4 interface resolves unclear binding mechanisms, enabling specific antagonists that reduce unwanted side effects.

A multi-marker stool assay detects SERPINF2 protein concentrations via targeted mass spectrometry for early diagnosis.

Monoclonal antibodies target phosphorylated ATR at position 1989, resolving low sensitivity in existing detection methods.

Blood RNA-Seq gene signatures classify sepsis mechanistic endotypes, resolving diagnostic heterogeneity and reducing unnecessary antibiotic use.

A synergistic antioxidant formulation combines sweetener and plant extracts to regulate physiological homeostasis.

Small molecules promote myosin II accumulation at contractile structures, increasing cellular cortical tension and modulating cell mechanics.

Segmented autoantibody panel differentiates systemic sclerosis subtypes from other autoimmune diseases, resolving diagnostic ambiguity.

ASB4-derived peptides bind MHC class I molecules on cancer stem cells, enabling selective CTL recognition and destroying the subpopulation driving recurrence.

A cell culture platform monitors biological interactions using interferometry to detect structural changes in the medium at interaction sites.

Antibody-toxin conjugates eliminate pro-fibrotic ADAM12+ stromal cells, reducing collagen accumulation and improving organ recovery in chronic lesions.

Replace invasive surgical diagnosis with serum marker analysis to improve diagnostic reliability.

Segmented primary and secondary binding agents coupled with rolling circle DNA amplification boost detection sensitivity for cell-cell interactions.

Identifies peripheral zone tumor cells through CD133 and VEGFR-2 markers to target residual disease after surgery.

Selective ClpP inhibition improves glucose tolerance while preserving essential protein degradation functions.

NMD agents reduce toxicity associated with TDP-43 proteins in neuronal cells, addressing the lack of effective treatments for amyotrophic lateral sclerosis.

Potassium channel openers modulate ion transmission through potassium channels to normalize electrical conductance in motor neurons.

Inhibiting XBP1 disrupts the UPR pathway to suppress tumor growth and prevent relapse in triple negative breast cancer.

A planar lipid bilayer system measures immunological synapse quality to predict chimeric antigen receptor T cell effectiveness.

A receptor array with hydrophobic through-holes measures eukaryotic cell activation degrees to quantify odor responses.

Thiol compounds target aberrant poly-IgA formation without broad immune suppression, addressing adverse events from conventional corticosteroid therapies.

Fc fusion mediates TSHR stability to resolve autoantibody interactions, enabling precise autoimmune disease diagnostics.

Surface plasmon resonance detects ligand binding to paddle motif peptides via refractive index changes, eliminating radioactive probes.

Antagonist non-depleting antibodies bind human OX40 to enhance regulatory T cell activity and suppressive function.

Targeted agents address FGFR2 or NTRK1 genetic alterations, improving survival rates for patients with advanced cholangiocarcinoma.

Luminescence-based chaperone interaction assay detects protein binding changes using labeled bait and prey complexes.

Identify Xkr8 modulators via phospholipid distribution changes to resolve unclear apoptotic scramblase identity.

Inverting passive aging models identifies compounds that actively regulate life expectancy by targeting mood-stress pathways.

Administered cells interact with splenocytes to increase anti-inflammatory cytokines and preserve splenic mass.